首页>投融资

T3 Pharmaceuticals

收并购

T3 Pharmaceuticals, founded in May 2015 as a spin-off of the University of Basel, is focused on bacteria-based therapies for the treatment of solid tumors.In July 2020, the company closed third financing round, raising over 25M CHF.In September 2019, the company raised over CHF 12 million (US $12.13 million) by closing of its second financing round

https://www.t3pharma.com/

470211

基本信息

公司全称

T3 Pharmaceuticals AG
类型

临床前生物制药商
产业领域

医药研发/制造、化学&生物药
公司人数

15人以下
地址

c/o Swiss TPH Kreuzstrasse 2 ALLSCHWIL BASEL-LANDSCHAFT 4123; CH;
联系电话

410612672074
邮箱

info@t3pharma.com
成立时间

2015-01-01

投融资

2024-02-22

并购

4.5亿瑞士法郎

Boehringer Ingelheim
2024-02-22

收并购

4.5亿瑞士法郎

Boehringer Ingelheim
2021-06-10

未公开

未透露

Swiss Economic Award
2021-06-10

未透露

未透露

Swiss Economic Award
2020-07-22

C轮

2500万瑞士法郎

Reference Capital SA

Wille Finance

Boehringer Ingelheim Venture Fund
2020-07-22

C轮

2500万瑞士法郎

勃林格殷格翰风险基金

Reference Capital SA

Wille Finance
2019-09-26

A轮

1200万瑞士法郎

Reference Capital SA

Boehringer Ingelheim Venture Fund
2019-09-26

A轮

未透露

Reference Capital SA

Boehringer Ingelheim Venture Fund
2019-09-26

A轮

1200万瑞士法郎

Reference Capital SA

勃林格殷格翰风险基金
2016-11-28

种子轮

未透露

未透露
2016-11-23

未公开

未透露

Swiss Federal Commission for Innovation and Technology
2016-11-23

未透露

未透露

Swiss Federal Commission for Innovation and Technology
加载更多

T3 Pharmaceuticals

基本信息

投融资

相关投融资企业